Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy;Resistencias genotípicas a los fármacos antirretrovirales en fracasos terapéuticos con pautas de alta eficacia

Medicina Clinica

Volumn 115, Issue 11, 2000, Pages 401-404

  Gutiérrez, Félix ^d,e   Moltó, José ^f   Escolano, Clara ^f   Mora, A ^f   Pasquau, Francisco ^a   Gregori, Joan ^b   Nogueira, Enrique ^c  

^a Servicio de Medicina Interna   (Spain)

^b HOSPITAL VEGA BAJA   (Spain)

^c Generalitat Valenciana   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^f NONE

Author keywords

Genotypic resistance; Highly active antiretroviral therapy; Human immunodeficiency virus infection; Therapeutic failures

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; TREATMENT FAILURE;

EID: 0343807004     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71574-0     Document Type: Article

References (14)

1. Deeks S, Hecht F, Swanson M, Elbeik T, Loftus R, Cohen P et al. HIV, RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35-F43.
2. Markowitz M. Resistance, fitness, adherence and potency. JAMA 2000; 283: 250-251.
3. Hecht F, Grant R, Petropoulos C, Dillon B, Chesney MA, Hellman N et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307-311.
4. Zazzi M, Riccio M, Venturi G, Catucci M, Romano L, De Milito A et al. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Mol Biotechnol 1998; 10: 1-8.
5. Shafer R, Stevenson D, Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 1999; 27: 348-352.
6. Rodriguez-Rosado R, Briones C, Soriano V. Introduction of HIV drug-resistance testing in clinical practice. AIDS 1999; 13: 1007-1014.
7. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS society-USA panel. JAMA 2000; 283: 2417-2426.
8. Durant J, Clevenbergh P, Halfon P, Delgudice P, Porsin S, Simonet P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353: 2195-2199.
9. Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V et al. Prevalence of genotipic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12: 1015-1020.
10. Puig T, Pérez-Olmeda M, Rubio A, Ruis L, Briones C, Franco JM et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000; 14: 727-732.
11. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-F127.
12. Lorenzi P, Opravil M, Hirschel B, Chave J, Furrer H, Sax H et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13: F17-F21.
13. Cozzi A, Sabin C, Staszewski S, Hertogs K, Müller A, Rabenau H et al. Resistance profiles in patients with viral rebound on potent antirretroviral therapy. J Infect Dis 2000; 181: 1143-1147.
14. Zolopa A, Schafer R, Warford A, Montoya J, Hsu P, Katzenstein D et al. HIV-1 genotypic resistance patterns predicts response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131: 813-821.